

Varenicline, a nicotinic receptor agonist for the treatment of Excessive Daytime Sleepiness in Parkinson's Disease: a placebo-controlled cross-over pilot study.

<https://www.neurodegenerationresearch.eu/survey/varenicline-a-nicotinic-receptor-agonist-for-the-treatment-of-excessive-daytime-sleepiness-in-parkinson%2s-disease-a-placebo-controlled-cross-over-pilot-study/>

Principal Investigators

dr. E.M.J. Foncke

Institution

Vumc

Contact information of lead PI

Country

Netherlands

Title of project or programme

Varenicline, a nicotinic receptor agonist for the treatment of Excessive Daytime Sleepiness in Parkinson's Disease: a placebo-controlled cross-over pilot study.

Source of funding information

Parkinson Vereniging

Total sum awarded (Euro)

€ 62,301

Start date of award

01/01/2015

Total duration of award in years

2

Keywords

Research Abstract

Sleep disturbances are common in Parkinson's disease and include excessive daytime sleepiness that has been reported in up to 50% of patients. Relatively little therapeutic research has addressed the problem of excessive daytime sleepiness and current treatment is largely

aimed at reducing the dose of dopaminergic medication while trying to maintain sufficient motor control which unfortunately often fails. Apart from degeneration of dopaminergic neurons, a decrease in cholinergic projections to the brain arousal areas may be at least partly responsible for the occurrence of excessive daytime sleepiness in Parkinson's disease. Smoking in narcoleptic patients diminishes sleep attacks and excessive daytime sleepiness, thus one may hypothesize that nicotinic stimulation of the brain arousal areas may improve excessive daytime sleepiness in Parkinson's disease. Therefore the effect of varenicline, an alpha4beta2 nicotinic receptor partial agonist, on excessive daytime sleepiness in Parkinson's disease will be studied in a placebo-controlled cross-over study. The effect of varenicline, an alpha4beta2 nicotinic receptor partial agonist on excessive daytime sleepiness in Parkinson's disease will be studied in a randomized, double blind, placebo-controlled clinical trial with a within-subject crossover design.

Further information available at:

<https://clinicaltrials.gov/ct2/show/NCT02473562>

Types:

Investments < €500k

Member States:

Netherlands

Diseases:

N/A

Years:

2016

Database Categories:

N/A

Database Tags:

N/A